David R Pearson: WILLOW study investigating enpatoran for the treatment of systemic and/or cutaneous lupus erythematosus

Touch Medical Media coverage of data presented at EADV:

WILLOW is a phase II, double-blind study investigating enpatoran for the treatment of systemic and/or cutaneous lupus erythematosus (NCT05162586). touchIMMUNOLOGY were delighted to speak with Dr. David R Pearson (University of Minnesota, Minneapolis, MN, USA) about the findings from preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran, and about the aims, eligibility criteria and primary and secondary outcome measures of the WILLOW study.

The abstract ‘Enpatoran: Preclinical Evidence Supporting Glucocorticoid Dose Reduction and Phase II Study Design in Patients with SLE and/or CLE (WILLOW).‘ (Abstract number: 1230) was presented at EADV 2022, 7-10 September, 2022.

Questions

1. Could you tell us a little about the preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran? (0:20)
2. What were the findings of these studies? (1:23)
3. What are the aims, design and eligibility criteria of the WILLOW study? (3:13)
4. What are the primary and secondary outcome measures of the study? (3:44)

Disclosures: David R Pearson discloses consulting for Biogen, Inc and receiving grant/ research support from Corbus, EMD Serono, Emerald Health, Kadmon, Pfizer, and Priovant.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.